Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CoMentis Inc.

www.comentis.com

Latest From CoMentis Inc.

Merck's Promising Early Alzheimer's Data Can't Quell Efficacy Concerns

The publication of Phase I analyses for Merck & Co.'s Alzheimer's therapy, verubecestat, may help to explain why the company decided to pursue costly Phase III studies without more data – but questions still remain around the drug's fundamental hypothesis that modulating the brain amyloid system will translate into a clinical response.

Neurology Clinical Trials

Cardax names ex-big pharma execs as directors

Development-stage life science company Cardax has named former Novartis, Bristol-Myers Squibb (BMS) and Boehringer Ingelheim (BI) employees as independent members of its board of directors. They are:

Startup Alzheon revives tramiprosate for Alzheimer's with license for prodrug

Lexington, Massachusetts-based startup Alzheon raised an undisclosed amount of private capital from two unidentified private investors to develop ALZ-801, a prodrug of the well-known Alzheimer's drug tramiprosate (Alzhemed), which failed in Phase III clinical trials.

Neurology Italy

Janssen touches BACE with Shionogi for early-stage Alzheimer's candidates

Janssen Pharmaceuticals has acquired rights to a series of oral inhibitors of the beta-site amyloid precursor protein-cleaving enzyme (BACE) in preclinical development for Alzheimer's disease at the Japanese firm Shionogi.

Neurology Japan
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Athenagen Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CoMentis Inc.
  • Senior Management
  • Carl F Grove, PhD, Pres. & CEO
    Terence Kelly, PhD, CSO
  • Contact Info
  • CoMentis Inc.
    Phone: (650) 869-7600
    280 Utah Ave.
    Ste. 275
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register